Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

People In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Stryker names new president and CEO, and more news on industry personnel shifts.

You may also be interested in...



People Briefs: Appointments At Covidien, Stryker, DaVita, InspireMD, JDRF

Covidien expands group president Bryan Hanson’s portfolio to include all business units. Stryker adds board chairmen role for CEO Kevin Lobo. More people news.

People Briefs: New CEO At Hologic; Departures At MDMA

Hologic appoints former Stryker CEO MacMillan president and CEO. Two staffers leave MDMA for device firms. More people briefs.

People In Brief

JenaValve, Predictive Biosciences, DexCom among firms with personnel news.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

News We’re Watching: Free COVID-19 Tests, Edwards Antitrust Investigation, McKinsey Calls For Medtech ‘Reinvention’

Proposed Rule Would Apply FDA’s Diagnostic Rules To LDTs

Four More Guidance Documents Released: Antimicrobial Devices, Closed-Loop Control Technology, De Novo Submissions, Devices For Graft Versus Host Diseases

Minute Insight: SpectralMD Signs Another Contract With BARDA, Worth $149m

See All
UsernamePublicRestriction

Register

MT031631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By